Evidence of altered Serotonergic Network in Parkinson’s disease by using a multi-modal MRI and PET imaging approach
Objective: This study aims to assess how serotonergic pathological derangement may produce alterations in Parkinson’s disease (PD) functional connectivity, by means of a multimodal neuroimaging…The role of LRP10 mutations in Parkinson’s Disease and Dementia with Lewy Bodies
Objective: To test LRP10 in a cohort of Italian patients, with a clinical diagnosis of either Parkinson’s Disease (PD) (n=316) or Dementia with Lewy Bodies…Cortical and subcortical atrophy in typical and variant Parkinson-plus syndromes: PROSPECT-M-UK study
Objective: To investigate grey matter volume in typical and variant Parkinson-plus syndromes, to correlate these with disease severity, and to assess regional atrophy within disease…Evaluation of corneal parameters in patients with idiopathic REM Sleep Behavior Disorder
Objective: To evaluate the blink rate (BR), tear function, and, corneal parameters of patients with iRBD. Background: In patients with Parkinson's disease (PD), dry eye…Long-term changes in myocardial sympathetic innervation and function in synucleinopathies
Objective: Describe long-term trends in indices of cardiac sympathetic innervation and function in synucleinopathies. Background: A group of neurodegenerative diseases including Parkinson disease (PD), pure…Premature State of Oligodendrocytes Potentially Provides Critical Period for Extracellular Pathological α-Synuclein to Invade Oligodendrocyte Lineage Cells
Objective: Multiple system atrophy (MSA) is pathologically characterized by accumulation of misfolded α-synuclein (α-syn) in oligodendrocytes (OLGs), which is known as glial cytoplasmic inclusions (GCIs).…Automated Interpretation of FP-CIT-SPECT images based on Artificial Intelligence
Objective: Our objective is to develop an AI-based approach to automatically rate FIP-CIT-SPECT data. Background: FP-CIT-SPECT visualizes the integrity of nigro-striatal dopaminergic synapses in vivo.…K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease
Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…Multiple system atrophy with predominant striato-nigral degeneration (MSA-P) and TDP-43 pathology: an unusual pathologic variant of MSA
Objective: To report a patient with MSA with concomitant occurrence of TDP-43-labeled and a-synuclein labeled inclusions in oligodendrocytes. Background: The pathologic hallmark in multiple system atrophy…Deciphering the role of posttranslational modifications on α-synuclein aggregation and toxicity
Objective: The precise contribution of alpha-synuclein (ASYN) to neuronal dysfunction and death is still unclear. There is intense debate on the nature of the toxic…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 15
- Next Page »